| Hepatocellular carcinoma in viral hepatitis: improving standard therapy. | |
| | |
MedLine Citation:
|
PMID: 19187872 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hepatocellular carcinoma (HCC) is a common malignancy worldwide, and its incidence is increasing in the United States and elsewhere. The prognosis of HCC patients depends not only on tumour stage but also on the background liver function reservoir. Current options for the treatment of HCC are surgical resection, liver transplantation, transcatheter arterial embolization, chemotherapy, and percutaneous ablation therapy. The choice of optimal treatment for individual patients, especially those at an earlier cancer stage, is sometimes controversial. Short-term prognosis of HCC patients has been much improved recently due to advances in early diagnosis and treatment, although long-term prognosis is as yet far from satisfactory as indicated by the overall survival at 10 years after apparently curative treatment of only 22-35%. Prevention of HCC recurrence, or tertiary prevention, is one of the most challenging tasks in current hepatology. |
| | |
Authors:
|
Ryota Masuzaki; Haruhiko Yoshida; Ryosuke Tateishi; Shuichiro Shiina; Masao Omata |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Best practice & research. Clinical gastroenterology Volume: 22 ISSN: 1532-1916 ISO Abbreviation: Best Pract Res Clin Gastroenterol Publication Date: 2008 |
Date Detail:
|
Created Date: 2009-02-03 Completed Date: 2009-04-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101120605 Medline TA: Best Pract Res Clin Gastroenterol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1137-51 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, University of Tokyo, Bunkyo-ku, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage Carcinoma, Hepatocellular / diagnosis, epidemiology*, therapy* Catheter Ablation Chemoembolization, Therapeutic Comorbidity Drug Delivery Systems Hepatectomy Hepatitis B / epidemiology* Hepatitis C / epidemiology* Humans Liver Neoplasms / diagnosis, epidemiology*, therapy* Liver Transplantation Primary Prevention Prognosis Randomized Controlled Trials as Topic Recurrence / prevention & control Tumor Markers, Biological |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Future treatment options for HCV: double, triple, what is the optimal combination?
Next Document: Liver transplantation in viral hepatitis: prevention of recurrence.